LONDON, March 2 (Reuters) - Haleon, the world's biggest standalone consumer health business, on Thursday forecast 4-6% organic revenue growth in 2023. (Reporting by Natalie Grover and Maggie Fick in London Editing by David Goodman )
GSK receives 'positive' headline results from phase III trial
(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.
Read more